PainChek Accelerates Global Reach with 10% Revenue Growth in Q2
PainChek Limited reports a robust quarter with a 10% rise in annual recurring revenue and expanding global client base, underpinned by strong licence retention and positive clinical validation.
- Net contracted licences rise 9% to 110,000
- Annual recurring revenue grows 10% to A$5.4 million
- Net licence retention rate exceeds 100%, indicating customer expansion
- New contracts secured in UK, Australia, and Canada with varied terms
- Scottish Inspectorate validation study supports broader adoption
Strong Sales Momentum
PainChek Limited, a pioneer in AI-driven pain assessment technology, has delivered a compelling sales update for the quarter ending June 2025. The company reported a 9% increase in net contracted licences, reaching 110,000, alongside a 10% uplift in annual recurring revenue (ARR) to A$5.4 million. These figures underscore sustained demand for PainChek’s innovative platform across multiple international markets.
Expanding Global Footprint
New client acquisitions span key regions including the United Kingdom, Australia, and Canada, reflecting PainChek’s successful geographic diversification strategy. The mix of one- and two-year subscription agreements, coupled with fixed implementation and billing schedules, suggests a maturing and scalable business model. This expansion is further validated by a net licence retention rate of 106%, indicating not only customer loyalty but also growth within existing accounts.
Clinical Validation and Market Positioning
Beyond commercial metrics, PainChek’s technology continues to gain clinical credibility. The Scottish Inspectorate’s recent validation study reported positive outcomes, positioning the company favorably within Scotland’s national aged care strategy review. This endorsement could pave the way for integration into broader healthcare frameworks, pending a forthcoming cost-benefit analysis by the Scottish Government.
Technology Impact and Future Prospects
With over 12 million global pain assessments conducted, PainChek’s AI-powered app is proving its clinical utility in improving pain management for vulnerable populations, including those with dementia and other conditions limiting self-reporting. CEO Philip Daffas highlighted a strong sales pipeline and upcoming product launches, signaling the company’s readiness for substantial growth in both existing and new markets.
Looking Ahead
As PainChek continues to build on its momentum, the company’s ability to convert clinical validation into widespread adoption will be critical. Its expansion into home care and disability services also opens new avenues for growth, potentially broadening its impact beyond residential aged care.
Bottom Line?
PainChek’s solid quarterly growth and clinical endorsements set the stage for accelerated expansion, but upcoming government reviews will be key to unlocking its full market potential.
Questions in the middle?
- How will the Scottish Government’s cost-benefit analysis influence PainChek’s adoption in national healthcare?
- What new products and geographies are next in PainChek’s growth pipeline?
- Can PainChek sustain its licence retention above 100% amid increasing competition?
